Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

We present an updated analysis of avapritinib efficacy and long-term safety in this patient population.

Source: European Journal of Cancer - January 16, 2021 Category: Cancer & Oncology Authors: Robin L. Jones, C ésar Serrano, Margaret von Mehren, Suzanne George, Michael C. Heinrich, Yoon-Koo Kang, Patrick Schöffski, Philippe A. Cassier, Olivier Mir, Sant P. Chawla, Ferry A.L.M. Eskens, Piotr Rutkowski, William D. Tap, Teresa Zhou, Maria Roche, Tags: Original Research Source Type: research